NZ629730A - Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage - Google Patents

Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage

Info

Publication number
NZ629730A
NZ629730A NZ629730A NZ62973014A NZ629730A NZ 629730 A NZ629730 A NZ 629730A NZ 629730 A NZ629730 A NZ 629730A NZ 62973014 A NZ62973014 A NZ 62973014A NZ 629730 A NZ629730 A NZ 629730A
Authority
NZ
New Zealand
Prior art keywords
compositions
aneurysmal subarachnoid
treat complications
subarachnoid hemorrhage
kda
Prior art date
Application number
NZ629730A
Other languages
English (en)
Inventor
Loch R Macdonald
Original Assignee
Edge Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edge Therapeutics Inc filed Critical Edge Therapeutics Inc
Publication of NZ629730A publication Critical patent/NZ629730A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ629730A 2013-03-11 2014-03-11 Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage NZ629730A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/793,767 US10092524B2 (en) 2008-06-11 2013-03-11 Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
PCT/US2014/023748 WO2014164904A1 (en) 2013-03-11 2014-03-11 Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage

Publications (1)

Publication Number Publication Date
NZ629730A true NZ629730A (en) 2017-03-31

Family

ID=49157870

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629730A NZ629730A (en) 2013-03-11 2014-03-11 Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage

Country Status (14)

Country Link
US (2) US10092524B2 (enExample)
EP (1) EP2968166A4 (enExample)
JP (1) JP2016512527A (enExample)
KR (1) KR101902319B1 (enExample)
CN (1) CN105324108A (enExample)
AU (1) AU2014248877A1 (enExample)
BR (1) BR112015022218A2 (enExample)
CA (1) CA2905327A1 (enExample)
GB (1) GB2528801A (enExample)
HK (1) HK1216002A1 (enExample)
NZ (1) NZ629730A (enExample)
RU (1) RU2015143206A (enExample)
SG (1) SG11201507398XA (enExample)
WO (1) WO2014164904A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
SG10201602665UA (en) 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow
CA2986692A1 (en) * 2015-05-29 2016-12-08 Edge Therapeutics, Inc. Compositions and methods for reducing visual loss
WO2017176914A1 (en) * 2016-04-07 2017-10-12 Edge Therapeutics, Inc. Formulations of site-specific, microparticulate compositions and their use to improve outcome after aneurysmal subarachnoid hemorrhage
CN108403629B (zh) * 2018-04-26 2019-11-05 徐州医科大学 一种尼莫地平口服长效悬浮液及其制备方法
WO2020227558A2 (en) * 2019-05-07 2020-11-12 Yale University Maximizing distribution and minimizing washout of injectates in bone and method for enhanced aspirate extraction
WO2020235947A1 (ko) * 2019-05-22 2020-11-26 경북대학교 산학협력단 Cacb1 유래 펩타이드, Cacb1 유래 펩타이드의 변이체 및 이의 용도
WO2021168351A1 (en) * 2020-02-20 2021-08-26 Postsurgical Therapeutics, Inc. Brain drug delivery system and method
WO2021262725A1 (en) * 2020-06-22 2021-12-30 Curelator, Inc. Systems and methods for segmentation of a user population based on time-based variations in biomarker levels
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
JP2024508888A (ja) * 2021-03-03 2024-02-28 クランメド リミテッド 一時的塞栓剤としてのアルギネートベースの粒子
WO2025151741A1 (en) * 2024-01-10 2025-07-17 Brown David Donaldson Methods of treating migraine headache or tension headache with hyaluronic acid

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5527893A (en) 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
ATE133087T1 (de) 1989-05-04 1996-02-15 Southern Res Inst Einkapselungsverfahren
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
EP0740791A4 (en) 1994-01-05 2000-04-05 Arqule Inc SYSTEMATIC MODULAR PRODUCTION OF AMINIMID AND OXAZOLONE-BASED MOLECULES WITH SELECTED PROPERTIES
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
AT404429B (de) 1995-06-09 1998-11-25 Immuno Ag Anti-plasma-antikörper-präparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
EP0932399B1 (en) 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
WO1998027963A2 (en) 1996-12-20 1998-07-02 Alza Corporation Gel composition and methods
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
WO1999018949A1 (en) 1997-10-15 1999-04-22 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
JP2000070366A (ja) 1998-09-02 2000-03-07 Arute:Kk 容器兼用注射器及び容器兼用注射器への凍結乾燥製剤の封入方法
US20050214227A1 (en) * 1999-03-08 2005-09-29 Powderject Research Limited Microparticle formulations for sustained-release of bioactive compounds
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US6284283B1 (en) 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
CA2396016A1 (en) 1999-12-29 2001-07-05 Andy Bernhardt System for reconstituting pastes and methods of using same
EP1250166B1 (en) 2000-01-25 2010-03-17 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002003406A (ja) 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
US20030032676A1 (en) 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
AU2002335658A1 (en) 2001-08-31 2003-03-18 Neuron Therapeutics, Inc. Treatment of neurologic hemorrhage
US20040235801A1 (en) 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
EP1459727B1 (en) 2001-11-22 2010-06-09 Japan Science and Technology Agency Nonhuman model animal unresponsive to immunopotentiating synthetic compound
JP2005524657A (ja) 2002-02-27 2005-08-18 ファーメイン, エルティーディー. 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
TW200307011A (en) 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
CN1665925A (zh) 2002-04-30 2005-09-07 马克西根控股公司 凝血因子Ⅶ或Ⅶa多肽变体
CN1671400A (zh) 2002-07-03 2005-09-21 派瑞克科学公司 透明质酸组合物以及使用方法
DK1553927T3 (da) 2002-09-11 2011-01-31 Elan Pharma Int Ltd Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
JP4092994B2 (ja) 2002-09-13 2008-05-28 ニプロ株式会社 プレフィルドシリンジキット
WO2004047768A2 (en) 2002-11-26 2004-06-10 Seacoast Neuroscience, Inc. Buoyant polymer particles delivering therapeutic agents
JP2007515392A (ja) 2003-04-10 2007-06-14 ピーアール ファーマシューティカルズ,インコーポレイテッド エマルジョンベースの微粒子の製造のための方法
US20070207211A1 (en) 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
CA2533592C (en) 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
WO2005042048A2 (en) 2003-10-22 2005-05-12 Encelle, Inc. Bioactive hydrogel compositions for regenerating connective tissue
WO2006002365A2 (en) 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US8034762B2 (en) 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2006084005A2 (en) 2005-02-02 2006-08-10 University Of Vermont And State Agricultural College Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
US20060217340A1 (en) 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity
EP1893230A2 (en) 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
JP2009501188A (ja) 2005-07-15 2009-01-15 ノボ ノルディスク ヘルス ケア アーゲー 抗血小板療法で治療される患者における脳内出血(ICH)後の出血増大及び/又は浮腫形成を予防又は軽減するための第VIIa因子又は第VIIa因子等価物の使用
GB0515492D0 (en) 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
WO2007047406A2 (en) 2005-10-14 2007-04-26 Transform Pharmaceuticals, Inc. Liquid pharmaceutical compositions of nimodipine
JP2009516751A (ja) 2005-11-21 2009-04-23 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティー・オブ・アラバマ・フォー・アンド・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アラバマ 神経保護のための小分子化合物を使用する方法
EP2108041A1 (en) 2007-01-18 2009-10-14 Reckitt Benckiser N.V. Dosage element and a method of manufacturing a dosage element
WO2008134541A2 (en) 2007-04-25 2008-11-06 Musculoskeletal Transplant Foundation Reinforced biological mesh for surgical reinforcement
US9005183B2 (en) 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
KR101554250B1 (ko) 2007-06-11 2015-09-18 알. 로치 맥도날드 뇌혈관 연축의 예방을 위한 약물 전달 시스템
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US20120164226A1 (en) 2007-06-11 2012-06-28 Leuthner Brian A Compositions and Methods for Improving Prognosis of a Human with Subarachnoid Hemorrhage
JP5502751B2 (ja) 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
CN102131496B (zh) 2008-08-22 2013-10-23 雷克特本克斯尔保健(英国)有限公司 组合物的改进或与组合物有关的改进
EP2331082B1 (en) 2008-09-11 2021-01-06 Evonik Corporation Solvent extraction microencapsulation with tunable extraction rates
EP2334288B1 (en) 2008-09-18 2021-05-19 Evonik Corporation Microencapsulation process with solvent and salt
US20100216948A1 (en) 2009-01-23 2010-08-26 Tipton Arthur J Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
WO2010085609A2 (en) 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
US20100291027A1 (en) 2009-05-14 2010-11-18 Jason Campbell Hyaluronic acid (ha) injection vehicle
US20110033463A1 (en) 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
WO2011087689A2 (en) 2009-12-22 2011-07-21 Surmodics Pharmaceuticals,Inc. Emulsion-based process for preparing microparticles and workhead assembly for use with same
GB2490084A (en) 2010-02-22 2012-10-17 Edge Therapeutics Inc Methods and compositions to treat hemorrhagic conditions of the brain
US9504643B2 (en) 2010-03-29 2016-11-29 Evonik Corporation Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
SG10201602665UA (en) 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof

Also Published As

Publication number Publication date
KR101902319B1 (ko) 2018-09-28
JP2016512527A (ja) 2016-04-28
RU2015143206A (ru) 2017-04-18
US20160324796A1 (en) 2016-11-10
GB201516997D0 (en) 2015-11-11
AU2014248877A1 (en) 2015-10-01
BR112015022218A2 (pt) 2017-07-18
EP2968166A1 (en) 2016-01-20
SG11201507398XA (en) 2015-10-29
EP2968166A4 (en) 2016-10-05
US20130243864A1 (en) 2013-09-19
KR20150136084A (ko) 2015-12-04
GB2528801A (en) 2016-02-03
AU2014248877A8 (en) 2015-10-29
HK1216002A1 (zh) 2016-10-07
CN105324108A (zh) 2016-02-10
US10092524B2 (en) 2018-10-09
WO2014164904A1 (en) 2014-10-09
CA2905327A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
NZ629730A (en) Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
EP4509520A3 (en) Silk protein fragment compositions and articles manufactured therefrom
IN2015DN04178A (enExample)
TW201612225A (en) Additive for LDS plastics
MX2015000921A (es) Polimeros de organopolisiloxano.
HK1214618A1 (zh) 含有透明質酸的穩定化組合物
MX340992B (es) Copolimeros de bloque para micelas estables.
PH12013501571A1 (en) Extensional viscosity to promote safe swallowing of food boluses
PH12016500393A1 (en) Furanoic polymer preforms, containers and processing
BR112014015909A2 (pt) composição
EP4541955A3 (en) Polymer composition comprising basic additive, process and articles comprising said polymer composition
CY1125511T1 (el) Συνθεση που περιλαμβανει χιτοζανη και ενα μυκητοκτονο
MX376192B (es) Articulo moldeado por inyeccion.
MX344487B (es) Polimeros de propileno-alfa-olefina, composiciones de adhesivos de fusion por calor que incluyen polimeros de propileno-alfa-olefina y articulos que los incluyen.
MX344635B (es) Composiciones y usos de materiales antimicrobianos con propiedades compatibles con el tejido.
MX2018012682A (es) Conjugados de acido hialuronico y usos de los mismos.
MX373828B (es) Composiciones poliméricas curables con humedad que tienen polímeros halogenados y mercáptidos de metal.
EA201890698A1 (ru) Химически инертный термоплавкий клей с улучшителем времени схватывания
MX2018006194A (es) Peptidos con propiedades antiangiogenicas, antilinfangiogenicas y antiedemicas y formulaciones de nanoparticulas.
IN2014DE03288A (enExample)
BR112015020895A2 (pt) composto de siloxano substancialmente linear, terminado em amina e produtos époxi feitos com o mesmo
EP2998338A4 (en) Highly functional polyamide polymer, spinning dope composition containing same, and molded product thereof
MX2016010231A (es) Conjugados del factor viii.
MX2016010229A (es) Conjugados del factor vii.
MX2016011440A (es) Promocion de la adhesion a sustratos dificiles para adhesivos de fusion en caliente.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2019 BY CPA GLOBAL

Effective date: 20180201

LAPS Patent lapsed